AUPH (Aurinia Pharmaceuticals) ROCE % : 13.97% (As of Sep. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Aurinia Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Aurinia Pharmaceuticals's annualized ROCE % for the quarter that ended in Sep. 2024 was 13.97%.

Aurinia Pharmaceuticals ROCE % Historical Data

The historical data trend for Aurinia Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurinia Pharmaceuticals ROCE % Chart

Aurinia Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-40.28

-28.01

-38.57

-22.93

-16.68

Aurinia Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-9.71	-21.10	-7.62	2.40	13.97

Aurinia Pharmaceuticals ROCE % Calculation

Aurinia Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-74.694	/	( ( (470.86 - 46.107)	+	(548.062 - 77.188) )	/ 2 )
	=	-74.694	/	( (424.753	+	470.874)	/ 2 )
	=	-74.694	/	447.8135
	=	-16.68 %

Aurinia Pharmaceuticals's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	64.06	/	( ( (523.529 - 76.903)	+	(549.361 - 78.609) )	/ 2 )
	=	64.06	/	( ( 446.626	+	470.752 )	/ 2 )
	=	64.06	/	458.689
	=	13.97 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Aurinia Pharmaceuticals (NAS:AUPH) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Aurinia Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Aurinia Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Aurinia Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aurinia Pharmaceuticals Inc (NAS:AUPH) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

IKAP:Germany IKAP:Germany

Address

14315 118 Avenue, Suite 140, Edmonton, AB, CAN, T5L 4S6

Website

https://www.auriniapharma.com

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.

Executives

Karen L. Smith	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Jeffrey Allen Bailey	director	BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Scott Michael Habig	officer: Chief Commercial Officer	#1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
R. Hector Mackay-dunn	director	#1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
Jayne David R.w.	director	#1203-4464 MARKHAM STREET, VICTORIA A1 BC V8Z7X8
Daniel Billen	director	#1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Jill Leversage	director	#1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Brinda Balakrishnan	director	#1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
Matthew Maxwell Donley	officer: Ex VP, Intern'l Operations	4520 EAST WEST HIGHWAY, 3RD FLOOR, BETHESDA MD 20814
Stephen P. Robertson	officer: EVP, General Counsel	#1203-4464 MARKHAM STREET, VICTORIA A1 BC V8Z7X8
Joseph M Miller	officer: Chief Financial Officer	C/O CERECOR INC., 400 EAST PRATT STREET, SUITE 606, BALTIMORE MD 21202
Peter Greenleaf	director, officer: Chief Executive Officer	ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Volker Knappertz	officer: EVP, Research and Development	SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB249BZ
Robert T Foster	director	C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
Joseph P Hagan	director	3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037